Professional Documents
Culture Documents
Absti Jurnal
Absti Jurnal
PICO
P: prevent malaria mortality in children in Plasmodium falciparum endemic areas and in
pregnancy.
I : Insecticide-treated mosquito nets (ITNs) and indoor-residual spraying (IRS)
C: with no Insecticide-treated mosquito nets (ITNs) and indoor-residual spraying (IRS)
O: protective efficacy (PE) of ITNs and IRS on reducing malaria-attributable mortality 1-59
months to be 55%, with a range of 49-61%, in P. falciparum settings. Malaria prevention
interventions in pregnancy (IPTp and ITNs) to have a pooled PE of 35% (95% confidence
interval: 23-45%) on reducing the prevalence of low birth weight (LBW) in the first or second
pregnancy in areas of stable P. falciparum transmission.
Pertanyaan klinis:
How is the protective efficacy PE of ITNs for reducing malaria-attributable mortality in
children , and the PE of IPTp and ITNs during pregnancy for reducing LBW?
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Abstract
BACKGROUND: One of the criteria to objectively prioritize merozoite antigens for malaria
vaccine development is the demonstration that naturally acquired antibodies are associated with
protection from malaria. However, published evidence of the protective effect of these antibodies
is conflicting.
CONCLUSIONS: These findings are valuable for advancing vaccine development by providing
evidence supporting merozoite antigens as targets of protective immunity in humans, and to help
identify antigens that confer protection from malaria. Further prospective cohort studies that
include a larger number of lead antigens and populations outside Africa are greatly needed to
ensure generalizability of results. The reporting of results needs to be standardized to maximize
comparability of studies. We therefore propose a set of guidelines to facilitate the uniform
reporting of malaria immuno-epidemiology observational studies. Please see later in the article
for the Editors' Summary.
MeSH Terms:
• Antibodies, Protozoan/blood*
• Antigens, Protozoan/immunology*
• Drug Design
• Evidence-Based Medicine
• Humans
• Incidence
• Malaria Vaccines/immunology*
• Malaria, Falciparum/diagnosis
• Malaria, Falciparum/epidemiology*
• Malaria, Falciparum/immunology
• Malaria, Falciparum/prevention & control
• Merozoites/immunology*
• Plasmodium falciparum/immunology*
• Protozoan Proteins/immunology*
Substances:
• Antibodies, Protozoan
• Antigens, Protozoan
• Malaria Vaccines
• Protozoan Proteins